SEC Company Response from PALISADE BIO, INC. (PALI) (CIK 0001357459) (PALI) — Jun 21, 2017
PALISADE BIO, INC. (PALI) (CIK 0001357459)
Date: June 21, 2017 · CIK: 0001357459 · Accession: 0001171843-17-003752
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218608
Referenced dates: June 20, 2017
Letter
Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission Registration Statement on Form S-3 Filed June 8, 2017 File No. 333-218608
RE: Neuralstem, Inc.
Dear Ms. Paik:
We are submitting this letter in response to your comment letter dated June 20, 2017 regarding the above referenced registration statement of Neuralstem, Inc. (“Company”). This response will follow the lineal order of your letter and each specific area addressed, utilizing the text of your letter as the primary guide:
Incorporation of Documents by Reference, Page 15
1. Please incorporate by reference the Current Reports on Form 8-K filed on January 6, February 16, February 22 and March 20, 2017. See Item 12(a)(2) of Form S-3.
Response: The Company has amended the Registration Statement as requested to comply with your comment. In addition, we have made conforming changes to page 11 of the warrant exercise prospectus.
Assuming there are no further comments from the Commission, the Company hereby requests that the above referenced registration statement be declared effective at 5:00 p.m. EST, on Friday June 23, 2017 or as soon as practicable thereafter.
We thank you in advance for your time and attention. Should you wish to further discuss this matter, please do not hesitate to contact me at 301.366.4960 or the Company’s counsel, Raul Silvestre of Silvestre Law Group, P.C. at 818.597.7552.
We hereby acknowledge that:
1. should the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, such action will not foreclose the Commission from taking any action with respect to the filing;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, will not relieve the Issuer from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
NEURALSTEM, INC.
3. The Issuer may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Richard Daly
Show Raw Text
CORRESP
1
filename1.htm
NEURALSTEM,
INC.
June 21, 2017
Irene Paik
Office of Healthcare and Insurance
Division of Corporation Finance
United States Securities and Exchange Commission
Washington, DC 20549
RE: Neuralstem, Inc.
Registration
Statement on Form S-3
Filed
June 8, 2017
File No.
333-218608
Dear Ms. Paik:
We are submitting this letter in response
to your comment letter dated June 20, 2017 regarding the above referenced registration statement of Neuralstem, Inc. (“Company”).
This response will follow the lineal order of your letter and each specific area addressed, utilizing the text of your letter as
the primary guide:
Incorporation of Documents by Reference,
Page 15
1. Please incorporate by reference the Current Reports on Form 8-K filed on January 6, February 16,
February 22 and March 20, 2017. See Item 12(a)(2) of Form S-3.
Response: The Company has amended the Registration Statement as requested to comply with your comment.
In addition, we have made conforming changes to page 11 of the warrant exercise prospectus.
Assuming there are no further comments
from the Commission, the Company hereby requests that the above referenced registration statement be declared effective at 5:00
p.m. EST, on Friday June 23, 2017 or as soon as practicable thereafter.
We thank you in advance for your time and
attention. Should you wish to further discuss this matter, please do not hesitate to contact me at 301.366.4960 or the Company’s
counsel, Raul Silvestre of Silvestre Law Group, P.C. at 818.597.7552.
We hereby acknowledge that:
1. should the Commission or the staff, acting pursuant to delegated authority, in declaring the filing
effective, such action will not foreclose the Commission from taking any action with respect to the filing;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, will not relieve the Issuer from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
1
NEURALSTEM,
INC.
3. The Issuer may not assert staff comments and the declaration of effectiveness as a defense in any
proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Richard Daly
Richard Daly
Chief Executive Officer
2